Plonmarlimab

普那利单抗

Report date: 2026/04/04 20:00:24

Base Information

Drug NamePlonmarlimab
Drug Alias NameTJ-003234RAR101TJM-2TJ-003234
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMacrophage colony stimulating factor 2 inhibitors
TargetsMacrophage colony stimulating factor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Macrophage Activation SyndromeLymphohistiocytosis, Hemophagocytic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesI-Mab Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesI-Mab Biopharma Us LtdTJ Biopharma(Hangzhou) Co LtdI-Mab Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Macrophage Activation SyndromeLymphohistiocytosis, Hemophagocytic +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A